Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Hiromitsu Fuse"'
Autor:
Ichiji Namatame, Kana Ishii, Takashi Shin, Daisuke Shimojo, Yukiko Yamagishi, Hidemitsu Asano, Yuuki Kishimoto, Hiromitsu Fuse, Yohei Nishi, Hidetoshi Sakurai, Tatsutoshi Nakahata, Haruna Sasaki-Iwaoka
Publikováno v:
SLAS Technology, Vol 28, Iss 5, Pp 351-360 (2023)
Due to their physiological relevance, cell-based assays using human-induced pluripotent stem cell (iPSC)-derived cells are a promising in vitro pharmacological evaluation system for drug candidates. However, cell-based assays involve complex processe
Externí odkaz:
https://doaj.org/article/4ec6426974f04615a35a7e1621a58788
Autor:
Yuko Kokubu, Tomoko Nagino, Katsunori Sasa, Tatsuo Oikawa, Katsuya Miyake, Akiko Kume, Mikiko Fukuda, Hiromitsu Fuse, Ryuichi Tozawa, Hidetoshi Sakurai
Publikováno v:
Stem Cells Translational Medicine, Vol 8, Iss 10, Pp 1017-1029 (2019)
Abstract Dysferlinopathy is a progressive muscle disorder that includes limb‐girdle muscular dystrophy type 2B and Miyoshi myopathy (MM). It is caused by mutations in the dysferlin (DYSF) gene, whose function is to reseal the muscular membrane. Tre
Externí odkaz:
https://doaj.org/article/b07e2c3175334def8fbba6cc177a30d7
Autor:
Hiroaki Nagai, Tomoko Satomi, Akiko Abiru, Kazumasa Miyamoto, Koji Nagasawa, Minoru Maruyama, Satoshi Yamamoto, Kuniko Kikuchi, Hiromitsu Fuse, Masakuni Noda, Yoshiyuki Tsujihata
Publikováno v:
EBioMedicine, Vol 24, Iss C, Pp 147-158 (2017)
Since impaired mitochondrial ATP production in cardiomyocytes is thought to lead to heart failure, a drug that protects mitochondria and improves ATP production under disease conditions would be an attractive treatment option. In this study, we ident
Externí odkaz:
https://doaj.org/article/5da0bd74b32a4b12af463c18fb53afa0
Autor:
Rina Hashimoto, Tomokazu Tamura, Yukio Watanabe, Ayaka Sakamoto, Naoko Yasuhara, Hayato Ito, Masahiro Nakano, Hiromitsu Fuse, Akira Ohta, Takeshi Noda, Yasufumi Matsumura, Miki Nagao, Takuya Yamamoto, Takasuke Fukuhara, Kazuo Takayama
Publikováno v:
Molecular Pharmaceutics. 20:2276-2287
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4bd8064da3974bb6de02d3beea1e8fef
https://doi.org/10.1021/acs.molpharmaceut.3c00114
https://doi.org/10.1021/acs.molpharmaceut.3c00114
Autor:
Akiko Kume, Tomoko Nagino, Katsunori Sasa, Hidetoshi Sakurai, Katsuya Miyake, Mikiko Fukuda, Ryuichi Tozawa, Tatsuo Oikawa, Yuko Kokubu, Hiromitsu Fuse
Publikováno v:
Stem Cells Translational Medicine, Vol 8, Iss 10, Pp 1017-1029 (2019)
Stem Cells Translational Medicine
Stem Cells Translational Medicine
Dysferlinopathy is a progressive muscle disorder that includes limb-girdle muscular dystrophy type 2B and Miyoshi myopathy (MM). It is caused by mutations in the dysferlin (DYSF) gene, whose function is to reseal the muscular membrane. Treatment with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7628d2448d55c740864418d077b3ec33
https://doaj.org/article/b07e2c3175334def8fbba6cc177a30d7
https://doaj.org/article/b07e2c3175334def8fbba6cc177a30d7
Autor:
Hiromitsu Fuse, Tatsutoshi Nakahata, Yohei Nishi, Daisuke Shimojo, Miho Sasamata, Haruna Sasaki-Iwaoka, Yukiko Yamagishi, Hidetoshi Sakurai
Publikováno v:
SLAS technology. 26(5)
Induced pluripotent stem cells (iPSCs) are attractive for use in early drug discovery because they can differentiate into any cell type. Maintenance cultures and differentiation processes for iPSCs, however, require a high level of technical expertis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c778a4e0086641f33702cc25ef933009
https://pubmed.ncbi.nlm.nih.gov/33775154
https://pubmed.ncbi.nlm.nih.gov/33775154
Autor:
Yoshiyuki Tsujihata, Tomoko Satomi, Satoshi Yamamoto, Kazumasa Miyamoto, Hiromitsu Fuse, Akiko Abiru, Hiroaki Nagai, Masakuni Noda, Koji Nagasawa, Minoru Maruyama, Kuniko Kikuchi
Publikováno v:
EBioMedicine, Vol 24, Iss C, Pp 147-158 (2017)
EBioMedicine
EBioMedicine
Since impaired mitochondrial ATP production in cardiomyocytes is thought to lead to heart failure, a drug that protects mitochondria and improves ATP production under disease conditions would be an attractive treatment option. In this study, we ident
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad9f78ce5cb5809ee38c68f0d53f5bba
http://www.sciencedirect.com/science/article/pii/S2352396417303766
http://www.sciencedirect.com/science/article/pii/S2352396417303766
Autor:
Hiroyuki Hozumi, Yoshitaka Yasuhara, Hiromitsu Fuse, Ryuichi Tozawa, Kimihiko Iwachidow, Masahiro Oka, Yusuke Moritoh
Publikováno v:
Scientific Reports
Inositol hexakisphosphate kinase 3 (IP6K3) generates inositol pyrophosphates, which regulate diverse cellular functions. However, little is known about its own physiological role. Here, we show the roles of IP6K3 in metabolic regulation. We detected
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fbc7368aec67c5a8e4b1ffe443a5459a
http://europepmc.org/articles/PMC5006000
http://europepmc.org/articles/PMC5006000
Autor:
Yuichi Kakoi, Yoshihisa Nakada, Masaki Ogino, Takeo Wada, Kazuki Kubo, Ryosuke Tokunoh, Hiromitsu Fuse, Shigekazu Itokawa, Seiji Fukui, Satoshi Nishimura, Shogo Marui, Tsukasa Sanada
Publikováno v:
Chemical and Pharmaceutical Bulletin. 59:1268-1273
Acyl-CoA: cholesterol acyltransferase (ACAT) is an intracellular enzyme that catalyzes cholesterol esterification. ACAT inhibitors are expected to be potent therapeutic agents for the treatment of atherosclerosis. A series of potent ACAT inhibitors b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c2a59943b8ef92e4358d4e002a3422d
https://doi.org/10.1248/cpb.59.1268
https://doi.org/10.1248/cpb.59.1268
Autor:
Hideaki Nagaya, Hiroki Sakamoto, Mami Ojima, Hideki Igata, Yasuhisa Kohara, Hiromitsu Fuse, Takanobu Kuroita, Tanaka Masayuki, Keiji Kubo, Keiji Kusumoto, Yoshimi Imura
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 336:801-808
The angiotensin II (AII) antagonistic action of azilsartan (AZL) [2-ethoxy-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylic acid] was investigated in radioligand binding and function studies. AZL inhi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8177bfe08a9259e2021485d591827ad
https://doi.org/10.1124/jpet.110.176636
https://doi.org/10.1124/jpet.110.176636